Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.

Eur Radiol 2019 Jun 5;29(6):3159-3169. Epub 2018 Dec 5.

UCL Centre for Medical Imaging, 2nd Floor Charles Bell House, 43 - 45 Foley Street, London, W1W 7TS, UK.

Objectives: To determine the diagnostic accuracy and interobserver concordance of whole-body (WB)-MRI, vs. Tc bone scintigraphy (BS) and fluoro-ethyl-choline (F-choline) PET/CT for the primary staging of intermediate/high-risk prostate cancer.

Methods: An institutional review board approved prospective cohort study carried out between July 2012 and November 2015, whereby 56 men prospectively underwent 3.0-T multiparametric (mp)-WB-MRI in addition to BS (all patients) ± F-choline PET/CT (33 patients). MRI comprised pre- and post-contrast modified Dixon (mDixon), T2-weighted (T2W) imaging, and diffusion-weighted imaging (DWI). Patients underwent follow-up mp-WB-MRI at 1 year to derive the reference standard. WB-MRIs were reviewed by two radiologists applying a 6-point scale and a locked sequential read (LSR) paradigm for the suspicion of nodal (N) and metastatic disease (M1a and M1b).

Results: The mean sensitivity/specificity of WB-MRI for N1 disease was 1.00/0.96 respectively, compared with 1.00/0.82 for F-choline PET/CT. The mean sensitivity and specificity of WB-MRI, F-choline PET/CT, and BS were 0.90/0.88, 0.80/0.92, and 0.60/1.00 for M1b disease. ROC-AUC did not show statistically significant improvement for each component of the LSR; mean ROC-AUC 0.92, 0.94, and 0.93 (p < 0.05) for mDixon + DWI, + T2WI, and + contrast respectively. WB-MRI had an interobserver concordance (κ) of 0.79, 0.68, and 0.58 for N1, M1a, and M1b diseases respectively.

Conclusions: WB-MRI provides high levels of diagnostic accuracy for both nodal and metastatic bone disease, with higher levels of sensitivity than BS for metastatic disease, and similar performance to F-choline PET/CT. T2 and post-contrast mDixon had no significant additive value above a protocol comprising mDixon and DWI alone.

Key Points: • A whole-body MRI protocol comprising unenhanced mDixon and diffusion-weighted imaging provides high levels of diagnostic accuracy for the primary staging of intermediate- and high-risk prostate cancer. • The diagnostic accuracy of whole-body MRI is much higher than that of bone scintigraphy, as currently recommended for clinical use. • Staging using WB-MRI, rather than bone scintigraphy, could result in better patient stratification and treatment delivery than is currently provided to patients worldwide.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-018-5813-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510859PMC
June 2019
20 Reads

Publication Analysis

Top Keywords

f-choline pet/ct
16
accuracy interobserver
8
diagnostic accuracy
8
nodal metastatic
8
pet/ct patients
4
patients mri
4
dixon mdixon
4
patients f-choline
4
addition patients
4
100/096 compared
4
pet/ct sensitivity
4
mri comprised
4
100/082 f-choline
4
post-contrast modified
4
pre- post-contrast
4
modified dixon
4
comprised pre-
4
compared 100/082
4
mp-wb-mri addition
4
july 2012
4

References

(Supplied by CrossRef)

MK Buyyounouski et al.
CA Cancer J Clin 2017

KD Linton et al.
Eur Urol 2012

FE Lecouvet et al.
Eur Urol 2012

Similar Publications